Skip to main content

Advertisement

SpringerLink
Log in

Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

There is no standard chemotherapy option for patients with biliary tract cancers. These patients present fairly ill and can have a rapid progression of disease. We conducted a multi-center, phase-II trial for patients with locally unresectable or metastatic bile duct or gallbladder adenocarcinomas using a modified regimen of gemcitabine and cisplatin to potentially improve tolerability. Patients received a 21-day treatment cycle of gemcitabine at 1,000 mg/m2 and cisplatin at 30 mg/m2 on days 1 and 8. To participate, 33 patients signed informed consent, and 30 patients received at least one dose of chemotherapy. By intention-to-treat analyses, 7 patients (21%) experienced a partial response and another 12 (36%) had stable disease for at least 12 weeks. The median progression-free survival was 6.3 months and median overall survival was 9.7 months. After 1 year, 39% of patients were alive. Most common grade 3–4 toxicities included neutropenia (33%), thrombocytopenia (23%), anemia (20%), nausea (20%), emesis (13%) and fatigue (10%). Of note, 52% of patients withdrew from study treatment, principally due to treatment-related adverse events. We concluded that this modified regimen appeared to have comparable activity to other gemcitabine and cisplatin regimens against advanced bile duct and gallbladder cancers, but there was still moderate toxicity in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  2. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  3. Eng C, Ramanathan RK, Wong MK et al (2004) A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 27:565–569

    Article  PubMed  CAS  Google Scholar 

  4. Gebbia V, Giuliani F, Maiello E et al (2001) Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19:4089–4091

    PubMed  CAS  Google Scholar 

  5. Kubicka S, Rudolph KL, Tietze MK et al (2001) Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783–789

    PubMed  CAS  Google Scholar 

  6. Lin MH, Chen JS, Chen HH et al (2003) A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49:154–158

    Article  PubMed  CAS  Google Scholar 

  7. Okusaka T, Ishii H, Funakoshi A et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57:647–653

    Article  PubMed  CAS  Google Scholar 

  8. Park JS, Oh SY, Kim SH et al (2005) Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 35:68–73

    Article  PubMed  Google Scholar 

  9. Penz M, Kornek GV, Raderer M et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183–186

    Article  PubMed  CAS  Google Scholar 

  10. Tsavaris N, Kosmas C, Gouveris P et al (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22:193–198

    Article  PubMed  CAS  Google Scholar 

  11. von Delius S, Lersch C, Schulte-Frohlinde E et al (2005) Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 5:61

    Article  CAS  Google Scholar 

  12. Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103:111–118

    Article  PubMed  CAS  Google Scholar 

  13. Andre T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339–1343

    Article  PubMed  CAS  Google Scholar 

  14. Bhargava P, Jani CR, Savarese DM et al (2003) Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park) 17:23–26

    Google Scholar 

  15. Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104:2753–2758

    Article  PubMed  CAS  Google Scholar 

  16. Doval DC, Sekhon JS, Gupta SK et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90:1516–1520

    Article  PubMed  CAS  Google Scholar 

  17. Hsu C, Shen YC, Yang CH et al (2004) Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 90:1715–1719

    PubMed  CAS  Google Scholar 

  18. Kim ST, Park JO, Lee J et al (2006) A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339–1346

    Article  PubMed  CAS  Google Scholar 

  19. Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332–2338

    Article  PubMed  CAS  Google Scholar 

  20. Knox JJ, Hedley D, Oza A et al (2004) Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 15:770–774

    Article  PubMed  CAS  Google Scholar 

  21. Kornek GV, Schuell B, Laengle F et al (2004) Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15:478–483

    Article  PubMed  CAS  Google Scholar 

  22. Kuhn R, Hribaschek A, Eichelmann K et al (2002) Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 20:351–356

    Article  PubMed  CAS  Google Scholar 

  23. Thongprasert S, Napapan S, Charoentum C et al (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279–281

    Article  PubMed  CAS  Google Scholar 

  24. Valle W, Wasan H, Johnson P et al (2006) Gemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinoma (CC) and other biliary tract tumors: a multicenter, randomized, phase II (the UK ABC-01) study, Gastrointestinal Cancer Symposium, pp Abstr 98

  25. Bergman AM, Ruiz van Haperen VW, Veerman G et al (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521–530

    PubMed  CAS  Google Scholar 

  26. Peters GJ, Bergman AM, Ruiz van Haperen VW et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72–79

    PubMed  CAS  Google Scholar 

  27. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  28. Rocha Lima CM, Flores AM (2006) Gemcitabine doublets in advanced pancreatic cancer: should we move on? J Clin Oncol 24:327–329

    Article  PubMed  Google Scholar 

  29. Heinemann V, Labianca R, Hinke A et al (2006) Superiority of gemcitabine plus platinum analog compared to gemcitabine alone in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study, Gastrointestinal Cancer Symposium, pp Abstr 96

Download references

Acknowledgment

Supported by Lilly Pharmaceuticals.

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Boston, MA, 02115, USA

    Jeffrey A. Meyerhardt, Nicole Lehman, Craig C. Earle, Matthew H. Kulke, Pankaj Bhargava & Charles S. Fuchs

  2. Massachusetts General Hospital, Boston, MA, USA

    Andrew X. Zhu, David P. Ryan & Lawrence Blaszkowsky

  3. Beth Israel Deaconess Medical Center, Boston, MA, USA

    Keith Stuart

Authors
  1. Jeffrey A. Meyerhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew X. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keith Stuart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David P. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lawrence Blaszkowsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicole Lehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Craig C. Earle
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Matthew H. Kulke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pankaj Bhargava
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Charles S. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey A. Meyerhardt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyerhardt, J.A., Zhu, A.X., Stuart, K. et al. Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. Dig Dis Sci 53, 564–570 (2008). https://doi.org/10.1007/s10620-007-9885-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9885-2

Keywords

Search

Navigation